Amyloid beta

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Monday, January 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Retrieved on: 
Wednesday, January 3, 2024
DSMB, AC, Immune system, Vaccine, ABATE, PET, Infection, CHF, PD, Amyloid beta, Pathology, Safety, Patient, Acceleration, Therapy, Tau

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune has continued steady clinical development progress throughout 2023, and we end the year in a very strong position.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune has continued steady clinical development progress throughout 2023, and we end the year in a very strong position.
  • We now have three active immunotherapies from our precision medicine pipeline in Phase 2 clinical testing, with key milestones for ACI-24.060 in 2024.
  • We are moving ever closer to delivering therapeutics that use the immune system to slow the onset and ultimately prevent neurodegenerative diseases, much like vaccines for infectious disease.
  • As recently announced, AC Immune’s development partner launched ReTain, a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical AD.

Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor

Retrieved on: 
Friday, December 29, 2023
CSF, Alzheimer's Research & Therapy, Alzheimer's disease, Dementia, Learning, Cerebrospinal fluid, Woman, Elastic net regularization, Heart rate, Sleep, Support vector machine, Hypertension, PET, Disease, Diabetes, Thyroid disease, Brain, Ageing, Risk, Stroke, Oita University, Faculty, Speech, Associate professor, Amyloid beta, Biomarker, Machine learning, Future Development, Manuscript, Transport, Patient, Medical school, Cardiovascular disease, MCI, AUC, Social isolation, Eisai, Area, Exercise, Medical imaging

TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (Aβ) accumulation in the brain using a wristband sensor.

Key Points: 
  • TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (Aβ) accumulation in the brain using a wristband sensor.
  • This model is expected to enable screening for brain Aβ accumulation, which is an important pathological factor of Alzheimer's disease*2 (AD), simply by collecting biological and lifestyle data from daily life.
  • The key to maximizing treatment effects of the medicine is detecting Abeta accumulation in the brain of patients with mild cognitive impairment before the onset of symptoms.
  • This machine learning model is able to predict brain Aβ accumulation using readily available non-invasive variables.

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders

Retrieved on: 
Tuesday, October 17, 2023
Identification, UMC, Cognition, Deficit spending, Research, Caregiver, Toxicity, Data, Cell therapy, Safety, Cogstate Brief Battery, Memory, Amsterdam, EEG, DSMB, Data monitoring committee, Fraunhofer Society, MCI, Immunology, QPCT, CBB, Pathology, AD, NTB, Patient, Euronext Amsterdam, Medical imaging, Pharmaceutical industry, Medical device, Amyloid beta

AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.

Key Points: 
  • AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.
  • It has the advantage of investigating a broad range of cognitive domains acknowledged to be clinically meaningful measures of function.
  • reliability and validity, support its use as an outcome measure in treatment evaluation studies and for use in clinical practice.
  • Based on the results in the SAPHIR study in early AD patients, theta power has been selected as a key secondary endpoint in the VIVIAD study.

Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference

Retrieved on: 
Monday, October 16, 2023
Senior, PAM, Donanemab, Lecanemab, Death, Amyloid, Brain, Clinical trial, PET, Disease, Clinical research, Neurology, Clarity, EDT, AD, Tropomyosin receptor kinase A, Research, Amyloid beta, Pharmaceutical industry, Medical imaging, MD, MPH, Alzheimer's disease, Eisai

The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.

Key Points: 
  • The conference will be held in Boston, Massachusetts, United States and virtually from October 24 to 27, 2023.
  • At the conference, Eisai will present data and research in five oral and ten poster presentations.
  • "We look forward to sharing the new LEQEMBI low-tau subgroup data and subcutaneous data at CTAD 2023."
  • The full list of presentations about Eisai assets and research, click the link: www.eisai.com/news/2023/news202365.html

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Amyloid-related imaging abnormalities, PMID, Outline, Clinical trial, Marketing, The New England Journal of Medicine, Deficit spending, Pathology, Ministry of Health, Labour and Welfare, Research, Brain, Siderosis, History, MCI, The Different Forms of Flowers on Plants of the Same Species, Clarity, Ministry, ARIA, Dementia, HIV disease progression rates, Patient, Immunoglobulin G, Superficial siderosis, PLOS One, Co-promotion, Ministry of Health (Kuwait), Therapy, Headache, Neurotoxicity, Disease, ADCS, Pharmaceutical industry, Alzheimer's disease, Biogen, Amyloid beta, Health, Eisai

Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.

Key Points: 
  • Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
  • In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • "Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease in Japan.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.

Eisai to Present the Latest Alzheimer's Disease Pipeline and Research

Retrieved on: 
Wednesday, July 12, 2023
Washington University in St. Louis, Senior, Disease, Amyloid beta, Alzheimer's Disease Neuroimaging Initiative, Pharmacokinetics, Research, Biomarker, MCI, Lecanemab, Downstream, AAIC, Patient, Clinical research, AIC, Poster, AD, Conference, Safety, Pharmaceutical industry, Alzheimer's disease, Domination, Eisai

The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.

Key Points: 
  • The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.
  • Eisai will present data and research in eight oral and 19 poster presentations at the meeting.
  • Two of the AAIC oral presentations will be presented as posters at the Alzheimer's Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.
  • "At AAIC 2023 Eisai will present the latest data on lecanemab, an anti-Aβ protofibril antibody, that recently received traditional approval in the U.S. for patients with mild cognitive impairment (MCI) due to AD and mild AD.

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, August 4, 2023
University of Geneva, Tau, University, The Michael J. Fox Foundation, Sahlgrenska University Hospital, Luxembourg Centre for Systems Biomedicine, Myawaddy Mingyi U Sa, ABATE, Tax, PET, Financial statement, AC, Gothenburg, Doctor of Philosophy, DS, Down syndrome, Target, University of Gothenburg, AAIC, MD, Patient, Medicine, Polhemus Memorial Clinic, Diagnosis, Poster, AD, FDA, CHF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, University of Luxembourg, ALS, Food, Conference, Safety, Geneva University Hospitals, D, Pharmaceutical industry, Medical imaging, Fine chemical, Vaccine, Amyloid beta

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.
  • The first patient with Parkinson’s disease was dosed in the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, AC Immune’s wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy.
  • The Company’s cash balance provides sufficient capital resources to progress into at least Q3 2024 without considering receipt of potential future milestone payments.
  • G&A Expenditures: G&A decreased by CHF 0.7 million to CHF 3.7 million, mostly due to a decrease in personnel expenses.